Portal de Periódicos da CAPES

Normalization of Height in Girls with Turner Syndrome after Long-Term Growth Hormone Treatment: Results of a Randomized Dose-Response Trial 1

1999; Oxford University Press; Volume: 84; Issue: 12 Linguagem: Inglês

10.1210/jcem.84.12.6241

1945-7197

Theo Sas, Sabine M.P.F. de Muinck Keizer‐Schrama, Theo Stijnen, M. Jansen, Barto J. Otten, J. J. Gera Hoorweg-Nijman, Thomas Vulsma, Guy Massa, Catrienus W. Rouwé, H.M. Reeser, Willem‐Jan M. Gerver, Jos J. Gosen, C. Rongen‐Westerlaken, Stenvert L. S. Drop,

Hypothalamic control of reproductive hormones

Short stature and ovarian failure are the main features in Turner syndrome (TS). To optimize GH and estrogen treatment, we studied 68 previously untreated girls with TS, age 2–11 yr, who were randomly assigned to one of three GH dosage groups: group A, 4 IU/m2·day (≈0.045 mg/kg·day); group B, first yr 4, thereafter 6 IU/m2·day (≈0.0675 mg/kg/day); group C, first yr 4, second yr 6, thereafter 8 IU/m2·day (≈0.090 mg/kg·day). In the first 4 yr of GH treatment, no estrogens for pubertal induction were given to the girls. Thereafter, girls started with 17β-estradiol (5 μg/kg bw·day, orally) when they had reached the age of 12 yr. Subjects were followed up until attainment of adult height or until cessation of treatment because of satisfaction with the height achieved.